{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:02:27Z","timestamp":1763535747145},"reference-count":89,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review aims to explore, present, and discuss disorders of glucose metabolism implicated in pituitary gland diseases, the appropriate interventions, as well as the therapeutic challenges that may arise. Pituitary pathologies may dysregulate glucose homeostasis, as both the excess and deficiency of various pituitary hormones can affect glucose metabolism. Increased circulating levels of growth hormone, glucocorticoids or prolactin have been shown to mainly provoke hyperglycemic states, while hypopituitarism can be associated with both hyperglycemia and hypoglycemia. Addressing the primary cause of these disorders with the use of surgery, medical treatment or radiotherapy forms the cornerstone of current management strategies. Physicians should bear in mind that some such medications have an unfavorable effect on glucose metabolism too. When unsuccessful, or until the appropriate treatment of the underlying pituitary problem, the addition of established antidiabetic therapies might prove useful. Further studies aiming to discover more accurate and effective drug preparations in combination with optimal lifestyle management models will contribute to achieving a more successful glycemic control in these patients.<\/jats:p>","DOI":"10.1055\/a-1258-8625","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T22:49:37Z","timestamp":1602542977000},"page":"16-23","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of Pituitary Gland Disorders on Glucose Metabolism: From Pathophysiology to Management"],"prefix":"10.1055","volume":"53","author":[{"given":"Guy I.","family":"Sydney","sequence":"additional","affiliation":[{"name":"Center for Pediatric Clinical Effectiveness, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Michalakis","sequence":"additional","affiliation":[{"name":"Imperial College of Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias P.","family":"Nikas","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios","family":"Spartalis","sequence":"additional","affiliation":[{"name":"2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, Nicosia, Cyprus"},{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000430819","article-title":"Glucose and fat metabolism in acromegaly: from mice models to patient care","volume":"103","author":"J Dal","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF00273860","article-title":"Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo","volume":"28","author":"G Schernthaner","year":"1985","journal-title":"Diabetologia"},{"key":"ref3","first-page":"175","article-title":"Insulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma","volume":"41","author":"B A Dogan","year":"2016","journal-title":"Minerva Endocrinol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jc.2011-3123","article-title":"Body composition and cardiovascular risk markers after remission of Cushing\u2019s Disease: A prospective study using whole-body MRI","volume":"97","author":"E B Geer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000314316","article-title":"Management of diabetes mellitus in cushing\u2019s syndrome","volume":"92","author":"A Munir","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance","volume":"43","author":"E B Geer","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.2013-2394","article-title":"Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH\u2014an update","volume":"99","author":"C Gazzaruso","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"A L Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ecl.2007.10.002","article-title":"Acromegaly","volume":"37","author":"A Ben-Shlomo","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref10","first-page":"E1856","article-title":"Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2\/STAT5 signal transduction and STAT5b DNA binding","volume":"292","author":"Y Chen","year":"2007","journal-title":"Am J Physiol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s42000-018-0066-9","article-title":"Growth hormone axis in patients with chronic kidney disease","volume":"18","author":"S A Paschou","year":"2019","journal-title":"Hormones"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ecl.2012.04.017","article-title":"Metabolic actions of insulin-like growth factor-i in normal physiology and diabetes","volume":"41","author":"D R Clemmons","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/diabetes.50.2007.S140","article-title":"IRS proteins and beta-cell function","volume":"50","author":"D J Burks","year":"2001","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jc.2008-1546","article-title":"Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study","volume":"94","author":"A Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"C L Ronchi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","article-title":"Glucose tolerance and somatostatin analog treatment in acromegaly: A 12-Month Study","volume":"94","author":"A Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"R Baldelli","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-015-0413-y","article-title":"Pasireotide in acromegaly: a review","volume":"75","author":"K McKeage","year":"2015","journal-title":"Drugs"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"R R Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","article-title":"Comparison of pegvisomant and long-acting octreotide in patients with acromegaly na\u00efve to radiation and medical therapy","volume":"32","author":"E Ghigo","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors","volume":"107","author":"E Bajetta","year":"2006","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: An in vitro study on isolated human pancreatic islets","volume":"92","author":"V Singh","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","author":"C Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1091-255X(97)80117-5","article-title":"Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas","volume":"1","author":"A Atiya","year":"1997","journal-title":"J Gastrointest Surg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/JOE-11-0224","article-title":"Effects of somatostatin analogs on glucose homeostasis in rats","volume":"212","author":"H A Schmid","year":"2012","journal-title":"J Endocrinol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2006.07.006","article-title":"Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues","volume":"138","author":"E Ludvigsen","year":"2007","journal-title":"Regul Pept"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.03996.x","article-title":"Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues","volume":"75","author":"M Tzanela","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-015-0404-6","article-title":"Italian Society for the study of diabetes (SID)\/italian endocrinological society (SIE) guidelines on the treatment of hyperglycemia in cushing\u2019s syndrome and acromegaly","volume":"39","author":"M G Baroni","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fendo.2019.00327","article-title":"Glucose abnormalities associated to prolactin secreting pituitary adenomas","volume":"10","author":"R S Auriemma","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2005.04.026","article-title":"Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue","volume":"331","author":"L Nilsson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1463-1326.2006.00671.x","article-title":"Adipocyte prolactin: regulation of release and putative functions","volume":"9","author":"T Brandebourg","year":"2007","journal-title":"Diabetes, Obes Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1210\/jc.2002-021137","article-title":"Identification of functional prolactin (PRL) receptor gene expression: prl inhibits lipoprotein lipase activity in human white adipose tissue","volume":"88","author":"C Ling","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.2337\/diabetes.54.7.1968","article-title":"The regulation of fatty acid synthase by STAT5A","volume":"54","author":"J C Hogan","year":"2005","journal-title":"Diabetes"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2337\/diabetes.52.2.268","article-title":"Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin","volume":"52","author":"T P Combs","year":"2003","journal-title":"Diabetes"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1677\/JOE-07-0043","article-title":"Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy","volume":"193","author":"A J Weinhaus","year":"2007","journal-title":"J Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2007-979040","article-title":"Adaptation of islets of langerhans to pregnancy: b-cell growth, enhanced insulin secretion and the role of lactogenic hormones","volume":"29","author":"R Sorenson","year":"1997","journal-title":"Horm Metab Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.mce.2006.09.011","article-title":"Beneficial effects of prolactin and laminin on human pancreatic islet-cell cultures","volume":"263","author":"L Labriola","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1210\/endo.142.7.8267","article-title":"Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5*","volume":"142","author":"D E Fleenor","year":"2001","journal-title":"Endocrinology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2009.02.031","article-title":"Immunomodulatory role of prolactin in diabetes development","volume":"9","author":"P Cejkova","year":"2009","journal-title":"Autoimmun Rev"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00745135","article-title":"Prolactin: a diabetogenic hormone","volume":"13","author":"R Landgraf","year":"1977","journal-title":"Diabetologia"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11102-009-0183-1","article-title":"Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique","volume":"12","author":"A Tuzcu","year":"2009","journal-title":"Pituitary"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/dmrr.1215","article-title":"Serum prolactin concentrations determine whether they improve or impair \u03b2-cell function and insulin sensitivity in diabetic rats","volume":"27","author":"S Park","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000336501","article-title":"Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats","volume":"95","author":"S Park","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine","author":"M Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1523\/JNEUROSCI.0129-12.2012","article-title":"Prolactin regulates tuberoinfundibular dopamine neuron discharge pattern: novel feedback control mechanisms in the lactotrophic axis","volume":"32","author":"D J Lyons","year":"2012","journal-title":"J Neurosci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy","volume":"14","author":"K Berinder","year":"2011","journal-title":"Pituitary"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: A Sympatholytic, D2-Dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"R A DeFronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.3109\/9780203217412-19","volume-title":"Hypothalamic role in the insulin resistance syndrome In: insulin resistance syndrome","author":"A H Cincotta","year":"2002"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1517\/13543784.8.10.1683","article-title":"Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes","volume":"8","author":"A H Cincotta","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"H Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-2009","article-title":"Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes","volume":"33","author":"J M Gaziano","year":"2010","journal-title":"Diabetes Care"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline","volume":"7","author":"N A Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"ref53","first-page":"2016","article-title":"Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males","author":"X Ruiz-Herrera","year":"2016","journal-title":"Endocrinology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00592-013-0493-7","article-title":"Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans","volume":"51","author":"R Wagner","year":"2014","journal-title":"Acta Diabetol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6823-13-12","article-title":"Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?","volume":"13","author":"L Balbach","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00125-018-4733-9","article-title":"Circulating prolactin concentrations and risk of type 2 diabetes in US women","volume":"61","author":"J Li","year":"2018","journal-title":"Diabetologia"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1006\/bbrc.2001.6307","article-title":"Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes","volume":"290","author":"M Fasshauer","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","article-title":"Management of endocrine disease: the burden of cushing\u2019s disease: clinical and health-related quality of life aspects","volume":"167","author":"R A Feelders","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"G Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-017-0860-9","article-title":"Diabetes in cushing disease","volume":"17","author":"G Mazziotti","year":"2017","journal-title":"Curr Diab Rep"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1210\/er.2016-1105","article-title":"Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management","volume":"38","author":"C Scaroni","year":"2017","journal-title":"Endocr Rev"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"L J Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s Disease","volume":"366","author":"A Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","article-title":"Pasireotide monotherapy in cushing\u2019s disease: a single-centre experience with 5-year extension of phase III trial","volume":"17","author":"J MacKenzie Feder","year":"2014","journal-title":"Pituitary"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","article-title":"Extended treatment of cushing\u2019s disease with pasireotide: results from a 2-year, phase II study","volume":"17","author":"M Boscaro","year":"2014","journal-title":"Pituitary"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"41","author":"M J Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"M133","DOI":"10.1530\/EJE-15-0354","article-title":"Metabolic comorbidities in cushing\u2019s syndrome","volume":"173","author":"F Ferrau","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"J Upadhyay","year":"2018","journal-title":"Metabolism"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in cushing\u2019s disease","author":"B Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"RC8","DOI":"10.1007\/BF03345281","article-title":"Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in cushing\u2019s disease","volume":"27","author":"S Cannavo","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in cushing\u2019s disease","volume":"90","author":"D Suri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"M Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced Glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"D H van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10928-016-9475-z","article-title":"Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose\u2013response analysis","volume":"43","author":"D J Conrado","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40265-013-0112-5","article-title":"11b-HSD1 Inhibitors for the treatment of type 2 diabetes and cardiovascular disease","volume":"73","author":"A Anderson","year":"2013","journal-title":"Drugs"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"N K Lee","year":"2007","journal-title":"Cell"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s42000-019-00147-z","article-title":"Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management","volume":"19","author":"K J Ioakim","year":"2020","journal-title":"Hormones"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/dmrr.1045","article-title":"The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced b-cell function in middle-aged male subjects","volume":"25","author":"Y-C Hwang","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2337\/dc09-1237","article-title":"Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus","volume":"33","author":"Y Winhofer","year":"2010","journal-title":"Diabetes Care"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-2005-861036","article-title":"Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome","volume":"37","author":"B L Herrmann","year":"2005","journal-title":"Horm Metab Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1210\/jc.2003-030278","article-title":"Adult-onset growth hormone deficiency: relation of postprandial dyslipidemia to premature atherosclerosis","volume":"88","author":"T B Twickler","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI20660","article-title":"The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity","volume":"113","author":"D R Clemmons","year":"2004","journal-title":"J Clin Invest"},{"key":"ref83","first-page":"E405","article-title":"Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice","volume":"287","author":"J-L Liu","year":"2004","journal-title":"Am J Physiol Metab"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1210\/en.2004-1203","article-title":"Pancreatic islet-specific expression of an insulin-like growth factor-i transgene compensates islet cell growth in growth hormone receptor gene-deficient mice","volume":"146","author":"Y Guo","year":"2005","journal-title":"Endocrinology"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1210\/jc.2004-0545","article-title":"Growth hormone and cardiovascular risk factors","volume":"90","author":"M Gola","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1210\/jc.2004-0894","article-title":"Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk","volume":"90","author":"K K Miller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2265.2005.02359.x","article-title":"Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency","volume":"63","author":"KC J Yuen","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3803\/EnM.2015.30.4.443","article-title":"Diagnosis and treatment of hypopituitarism","volume":"30","author":"S Y Kim","year":"2015","journal-title":"Endocrinol Metab"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.maturitas.2016.08.006","article-title":"Pituitary incidentalomas: a guide to assessment, treatment and follow-up","volume":"92","author":"S A Paschou","year":"2016","journal-title":"Maturitas"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1258-8625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:58:12Z","timestamp":1669168692000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1258-8625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":89,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,4]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1258-8625","relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}